Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results. This is an ASCO Meeting Abstract from the 2024 ...
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results